Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Go back to Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML| (NASDAQ: ELVN) | Delayed: 45.96 +0.86 (1.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $45.10 | 52 Week High | $ | |||
| Open | $45.26 | 52 Week Low | $ | |||
| Day High | $48.52 | P/E | N/A | |||
| Day Low | $45.25 | EPS | $ | |||
| Volume | 2,517,233 | |||||
